	(	(Original Signature of Member)
118TH CONGRESS 1ST SESSION	H.R.	

To increase funding for cancer research by the National Cancer Institute to be more in proportion to the mortality rates of cancer.

## IN THE HOUSE OF REPRESENTATIVES

Mr.	FITZPATRICK introduced	the	following	bill;	which	was	referred	to	the
	Committee on								

## A BILL

To increase funding for cancer research by the National Cancer Institute to be more in proportion to the mortality rates of cancer.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Knock Out Cancer
- 5 Act" or the "KO Cancer Act".
- 6 SEC. 2. INCREASING NCI BUDGET FOR CANCER RESEARCH.
- 7 To conduct or support cancer research, there is here-
- 8 by appropriated, for each of fiscal years 2024 through

1	2028, to the National Cancer Institute, out of amounts
2	in the Treasury not otherwise appropriated, an amount
3	that is equal to 25 percent of the total amount appro-
4	priated to the National Cancer Institute for fiscal year
5	2022, to remain available until expended. Amounts appro-
6	priated pursuant to the preceding sentence shall be in ad-
7	dition to amounts otherwise made available to the Na-
8	tional Cancer Institute.
9	SEC. 3. REPORT TO CONGRESS ON CANCER DRUG SHORT-
10	AGES.
11	(a) STUDY.—The Secretary of Health and Human
12	Services, acting through the Commissioner of Food and
13	Drugs, in collaboration with such other agencies as the
14	Secretary deems necessary, shall study the reasons for
15	cancer drug shortages, including—
16	(1) economic reasons;
17	(2) supply chain failures;
18	(3) delays and other complications relating to—
19	(A) the development of cancer drugs; and
20	(B) the approval of such drugs by the
21	Food and Drug Administration; and
22	(4) insufficient generic drugs and biosimilar bi-
23	ological products.
24	(b) Report.—

1	(1) IN GENERAL.—Not later than 1 year after
2	the date of enactment of this Act, the Secretary of
3	Health and Human Services, acting through the
4	Commissioner of Food and Drugs, shall complete
5	the study under subsection (a) and submit a report
6	to the appropriate committees of the Congress on
7	the results of such study.
8	(2) RECOMMENDATIONS.—The report under
9	paragraph (1) shall include recommendations for ad-
10	dressing the reasons for cancer drug shortages.